Merck, Bayer’s heart failure therapy Verquvo now approved for use across Europe

WORLD – Verquvo, a drug developed for the treatment of symptomatic chronic heart failure has been cleared for use by the European Commission (EC). The approval reflects another important regulatory milestone in the development of the medicine which will provide doctors, health care professionals and patients with an important treatment option to complement currently available heart failure therapies. Merck and Bayer jointly co-developed Verquvo with Merck holding the commercial rights to the heart failure drug in the US and Bayer having exclusive commercial rights globally. The drug relayed successful data…

Read More

Diabetes tech market continues to witness an upward trend as more companies are coming up with new innovations

US – Despite the volatility of last year’s economy due to the corona virus pandemic, diabetes technology companies experienced tremendous success. Analysts have been bullish on the market as companies target new patient populations and major product launches have been planned for 2021 with clinicians approving of the same. Recent surveys of healthcare professionals projecting both the use of continuous glucose monitors and insulin pumps to jump in the coming years. While continuous glucose monitoring (CGMs) and insulin pumps are the primary devices in diabetes tech, the space is also…

Read More

Merck and BioMedX set to partner as they strive to bolster their fight against cancer in a new joint cancer research programme

GERMANY – German based pharma company, Merck, and BioMed X, an independent research institute located at the University of Heidelberg in Germany have partnered to focus on their oncology related research. This is the eighth collaboration between the two organizations and is set to explore the role of extrachromosomal DNA (ecDNA) in cancer. BioMedX currently has two other ongoing oncology related programmes focused on DNA damage response and RNA splicing that this new research program is set to compliment. Extrachromosomal DNA (ecDNA) is any DNA that is found off the…

Read More

Lilly’s tirzepatide tops list ahead of ozempic as treatment candidate for type 2 diabetes

US – In the just concluded phase 3 trials, the American pharmaceutical company, Eli Lilly have provided results that showed its investigational Gastric inhibitory polypeptide (GIP) and Glucagon-like peptide 1 (GLP-1) inhibitor tirzepatide is superior to Novo Nordisk’s ozempic. The SURPASS-2 study compared the efficacy and safety of tirzepatide 5 mg, 10 mg and 15 mg to Ozempic (semaglutide) 1 mg in adults with inadequately controlled type 2 diabetes, as an add-on to metformin, a prescription medication used to treat diabetes. All three doses of Lilly’s drug demonstrated superior HbA1C…

Read More